ClinicalTrials.gg
TerminatedNCT04187404SpencerUpdated Jan 30, 2026Results posted

A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma

A Phase 1/2 interventional study of EO2401 and Nivolumab in Adrenocortical Carcinoma, Pheochromocytoma and Paraganglioma, sponsored by Enterome. Terminated at 12 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-30.

Sponsored by Enterome · Phase 1/2, Interventional, and Treatment

How we know · 8 judgments

Why this study was terminated
Strategic decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a multicenter, Phase 1/2, First-In-Human study to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma.

Read the detailed description

EO2401 is an innovative cancer peptide therapeutic vaccine based on the homologies between Tumor Associated Antigens and microbiome-derived peptides that will be administered in combination with nivolumab to generate preliminary safety and efficacy data in patients with Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma.

02

Conditions studied

  • Adrenocortical Carcinoma
  • Pheochromocytoma
  • Paraganglioma

Keywords

  • adrenocortical carcinoma
  • pheochromocytoma
  • paraganglioma
03

In context

Adrenocortical Carcinoma

94 studies on the registry are indexed under Adrenocortical Carcinoma; 26 are open to participants now.

This study's enrollment of 70 is above the median of 35 across 71 interventional studies indexed under Adrenocortical Carcinoma.

Browse Adrenocortical Carcinoma studies →

Lead sponsor

Enterome is the lead sponsor of 8 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  1. For inclusion in Cohort 1 patients should have adrenocortical carcinoma(ACC), or malignant pheochromocytoma/paraganglioma (MPP), as defined below for Cohorts 2A and 3A.
  2. For inclusion in Cohorts 2A and 2B patients should have confirmed (at primary diagnosis) unresectable locally advanced or adrenocortical carcinoma.
  3. For inclusion in Cohorts 3A and 3B patients should have histologically confirmed (at primary diagnosis) unresectable malignant (defined as metastatic disease, i.e. presence of chromaffin tissue in non-chromaffin organs) pheochromocytoma/paraganglioma, and defined progression should have been documented during a maximum of an 18-months period.
  4. Patients with an age ≥ 18 years old.
  5. Patients who are human leukocyte antigen (HLA)-A2 positive.
  6. Patients with an (ECOG) performance status ≤ 1.
  7. Patients with a > 4 months as judged by their treating physician.
  8. Patients with at least one according to RECIST 1.1.
  9. Males or non-pregnant, non-lactating, females.
  10. Patients willing and able to comply with the scheduled visits, treatment plan, laboratory tests, and other study procedures indicated in the protocol.
  11. Patients having received the information sheet and who have provided written prior to any study-related procedures.

Main Exclusion Criteria:

  1. Patients treated with dexamethasone > 2 mg/day or equivalent (i.e. 13 mg/day of prednisone, or 53 mg/day of hydrocortisone) within 14 days before the first EO2401 administration, unless required to treat an adverse event.
  2. Patients with prior treatment with immune check-point inhibitors
  3. Patients with prior exposure to EO2401.
  4. Patients treated with immunotherapy (meaning immunostimulatory or therapy; beside excluded, or allowed, compounds per other inclusion/exclusion criteria specifications), radionuclide therapy, radiotherapy, cytoreductive therapy, or received treatment with any other agent within 28 days before the first EO2401 administration.
  5. Patients with an initial diagnosis of ACC less than 9 months from start of screening part 2.
  6. Patients with ACC and any individual lesion according to RECIST 1.1 having a maximum diameter of more than 125 mm; irrespective if the lesion is proposed as a target lesion, or not, according to RECIST 1.1.
  7. Patients with ACC with more than three organs involved by disease, combined with unresectable primary tumor.
  8. Patients with ACC and uncontrolled hormonal secretion (according to the judgement of the treating physician).
  9. Patients with MPP and uncontrolled blood pressure (according to the judgement of the treating physician).
  10. Patients with abnormal laboratory values.
  11. Patients with persistent Grade 3 or 4 toxicities.
  12. Uncontrolled central nervous system (CNS) metastasis.
  13. Other or prior malignancy with a disease-free interval of less than 3 years
  14. Patients with disease.
  15. Patients with suspected or active autoimmune disorder or known history of an autoimmune neurologic condition (e.g. Guillain-Barré syndrome).
  16. Patients with history of solid organ transplantation or hematopoietic stem cell transplantation.
  17. Patients with history or known presence of tuberculosis.
  18. Pregnant and breastfeeding patients.
  19. Patients with history or presence of and/or potentially active virus/ virus infection.
  20. Patients who have received live or attenuated vaccine therapy used for prevention of infectious diseases including seasonal (influenza) vaccinations within 4 weeks of the first dose of study drug.
  21. Patients with a history of to any present in the pharmaceutical forms of the study treatments.
  22. Patients treated with herbal remedies with immunostimulating properties or known to potentially interfere with major organ function.
  23. Patients with known ongoing drug and alcohol abuse.
  24. Patients with known or underlying medical or psychiatric condition that, in the Investigator's opinion, would make the administration of study drug hazardous to the patient or obscure the interpretation of toxicity determination or AEs.
  25. Patients deprived of their liberty, under protective custody, or guardship.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    5-cohort study design

    Cohort 1:3-by-3 design of EO2401 in combination with nivolumab at standard dose. Three to 12 evaluable patients with adrenal carcinoma or progressive malignant pheochromocytoma/paraganglioma will be included depending on the safety profile of the administered treatments. Cohorts 2A (previously treated patients) and 2B (previously untreated patients): evaluation of EO2401in combination with nivolumab in 33 patients with adrenal carcinoma. Cohorts 3A (previously treated patients) and 3B (previously untreated patients) : evaluation of EO2401 combination with nivolumab in 20 patients (globally for both Cohorts 3A and 3B) with progressive malignant pheochromocytoma/ paraganglioma.

    Biological: EO2401 · Biological: Nivolumab

  • Experimental
    randomized extension of Cohort 2A (3 arms): C2A-I

    Randomized extension of Cohort 2A (65 patients using a 4:1:1 ratio): 43 patients belonging to this extension of Cohort 2A will be treated by EO2401 and nivolumab in combination.

    Biological: EO2401 · Biological: Nivolumab

  • Experimental
    randomized extension of Cohort 2A (3 arms): C2A-II

    11 patients belonging to this extension of Cohort 2A will be treated by EO2401 alone.

    Biological: EO2401

  • Active comparator
    randomized extension of Cohort 2A (3 arms): C2A-III

    11 patients belonging to this extension of Cohort 2A who will be treated by nivolumab alone.

    Biological: Nivolumab

Interventions

  • BiologicalEO2401

    Multiple dose of EO2401

  • BiologicalNivolumab

    Multiple dose of nivolumab

06

What researchers measure

Primary outcomes

  1. Treatment-Emergent Serious Adverse Events Assessment

    Incidences of treatment-emergent serious adverse events using the National Cancer Institute-Common Terminology Criteria for AEs (NCI-CTCAE) v5.0.

    Time frame: 46 months maximum (from baseline up to study end)

  2. Treatment-Emergent Non-Serious Adverse Events

    Incidences of treatment-emergent non-serious adverse events using the National Cancer Institute-Common Terminology Criteria for AEs (NCI-CTCAE) v5.0.

    Time frame: 46 months maximum (from baseline up to study end)

  3. All Cause Mortalities Assessment

    Incidence of death

    Time frame: 46 months maximum (from baseline up to study end)

Secondary outcomes

  1. Evaluation of Progression Free Survival

    Progression Free Survival according to iRECIST criteria at 6 months

    Time frame: 6 months after treatment start

  2. Evaluation of Survival

    Overall survival, defined as the time interval from the date of first study treatment administration to the date of death due to any cause

    Time frame: 46 months maximum (from baseline up to study end)

  3. Percentage of Patients With Immunogenicity Against EO2401

    Expansion of specific T cells comparing samples taken at baseline versus on treatment in an individual patient determining if the patient has a positive response to peptides that compose EO2401, or not. EO2401 immunogenicity is assessed by interferon-gamma (IFN-γ) enzyme-linked immunospot (ELISpot) (IVS and ex vivo).

    Time frame: 7 weeks after treatment start

07

Results

Posted Jan 30, 2026

Participant flow

Cohort 1 safety lead-in assessed safety and tolerability of EO2401 in combination with nivolumab during 4 weeks. Evaluable patients in Cohort 1 will be assessed as part of the planned Cohorts 2A (non-randomized) and 3A, respectively. The schedule of EO2401 and nivolumab administrations are the same in Cohorts 2A (non randomized) and Cohort 3A as in Cohort 1.

Participant flow — Overall Study
MilestoneCohort 2A (Non-randomized)Randomized Extension of Cohort 2A (3 Arms): C2A-IRandomized Extension of Cohort 2A (3 Arms): C2A-IIRandomized Extension of Cohort 2A (3 Arms): C2A-IIICohort 2B (Non-randomized)Cohort 3A (Non-randomized)Cohort 3B (Non-randomized)
Started2613247135
Started and originally enrolled in cohort 1 (safety lead-in).2000010
Completed2613247135
Not completed0000000

Outcome measures

PrimaryTreatment-Emergent Serious Adverse Events Assessment

Incidences of treatment-emergent serious adverse events using the National Cancer Institute-Common Terminology Criteria for AEs (NCI-CTCAE) v5.0.

Time frame:
46 months maximum (from baseline up to study end)
Reported as:
Count of participants · Participants
Treatment-Emergent Serious Adverse Events Assessment
ParticipantsCohort 2A (Non-randomized)Randomized Extension of Cohort 2A (3 Arms): C2A-IRandomized Extension of Cohort 2A (3 Arms): C2A-IIRandomized Extension of Cohort 2A (3 Arms): C2A-IIICohort 2B (Non-randomized)Cohort 3A (Non-randomized)Cohort 3B (Non-randomized)
Treatment-Emergent Serious Adverse Events Assessment5410142
PrimaryTreatment-Emergent Non-Serious Adverse Events

Incidences of treatment-emergent non-serious adverse events using the National Cancer Institute-Common Terminology Criteria for AEs (NCI-CTCAE) v5.0.

Time frame:
46 months maximum (from baseline up to study end)
Reported as:
Count of participants · Participants
Treatment-Emergent Non-Serious Adverse Events
ParticipantsCohort 2A (Non-randomized)Randomized Extension of Cohort 2A (3 Arms): C2A-IRandomized Extension of Cohort 2A (3 Arms): C2A-IIRandomized Extension of Cohort 2A (3 Arms): C2A-IIICohort 2B (Non-randomized)Cohort 3A (Non-randomized)Cohort 3B (Non-randomized)
Treatment-Emergent Non-Serious Adverse Events2613247135
PrimaryAll Cause Mortalities Assessment

Incidence of death

Time frame:
46 months maximum (from baseline up to study end)
Reported as:
Count of participants · Participants
All Cause Mortalities Assessment
ParticipantsCohort 21 (Non-randomized)Randomized Extension of Cohort 2A (3 Arms): C2A-IRandomized Extension of Cohort 2A (3 Arms): C2A-IIRandomized Extension of Cohort 2A (3 Arms): C2A-IIICohort 2B (Non-randomized)Cohort 3A (Non-randomized)Cohort 3B (Non-randomized)
All Cause Mortalities Assessment21512690
SecondaryEvaluation of Progression Free Survival

Progression Free Survival according to iRECIST criteria at 6 months

Time frame:
6 months after treatment start
Reported as:
Median · months
Evaluation of Progression Free Survival
monthsCohort 2A (Non-randomized)Randomized Extension of Cohort 2A (3 Arms): C2A-IRandomized Extension of Cohort 2A (3 Arms): C2A-IIRandomized Extension of Cohort 2A (3 Arms): C2A-IIICohort 2B (Non-randomized)Cohort 3A (Non-randomized)Cohort 3B (Non-randomized)
Evaluation of Progression Free Survival1.9 (1.8 to 2.3)1.9 (1.7 to 2.5)1.6 (1.2 to NA)1.7 (1.2 to NA)1.9 (1.2 to 2.7)5.2 (1.9 to 12.2)19.4 (3.9 to NA)
SecondaryEvaluation of Survival

Overall survival, defined as the time interval from the date of first study treatment administration to the date of death due to any cause

Time frame:
46 months maximum (from baseline up to study end)
Reported as:
Median · months
Evaluation of Survival
monthsCohort 2A (Non-randomized)Randomized Extension of Cohort 2A (3 Arms): C2A-IRandomized Extension of Cohort 2A (3 Arms): C2A-IIRandomized Extension of Cohort 2A (3 Arms): C2A-IIICohort 2B (Non-randomized)Cohort 3A (Non-randomized)Cohort 3B (Non-randomized)
Evaluation of Survival11.9 (2.2 to 22.9)NA (8.6 to NA)NA (3.0 to NA)NA (1.6 to NA)24.2 (1.2 to 33.5)11.4 (4.6 to NA)NA (NA to NA)
SecondaryPercentage of Patients With Immunogenicity Against EO2401

Expansion of specific T cells comparing samples taken at baseline versus on treatment in an individual patient determining if the patient has a positive response to peptides that compose EO2401, or not. EO2401 immunogenicity is assessed by interferon-gamma (IFN-γ) enzyme-linked immunospot (ELISpot) (IVS and ex vivo).

Time frame:
7 weeks after treatment start
Reported as:
Count of participants · Participants
Percentage of Patients With Immunogenicity Against EO2401
ParticipantsCohort 2A (Non-randomized)Randomized Extension of Cohort 2A (3 Arms): C2A-IRandomized Extension of Cohort 2A (3 Arms): C2A-IIRandomized Extension of Cohort 2A (3 Arms): C2A-IIICohort 2B (Non-randomized)Cohort 3A (Non-randomized)Cohort 3B (Non-randomized)
Percentage of Patients With Immunogenicity Against EO240112800352

Adverse events

Collected over 46 months maximum (from baseline up to study end). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 2A (Non-randomized)21/26 (80.8%)5/26 (19.2%)26/26 (100%)
Randomized Extension of Cohort 2A (3 Arms): C2A-I5/13 (38.5%)4/13 (30.8%)13/13 (100%)
Randomized Extension of Cohort 2A (3 Arms): C2A-II1/2 (50%)1/2 (50%)2/2 (100%)
Randomized Extension of Cohort 2A (3 Arms): C2A-III2/4 (50%)0/4 (0%)4/4 (100%)
Cohort 2B (Non-randomized)6/7 (85.7%)1/7 (14.3%)7/7 (100%)
Cohort 3A (Non-randomized)9/13 (69.2%)4/13 (30.8%)13/13 (100%)
Cohort 3B (Non-randomized)0/5 (0%)2/5 (40%)5/5 (100%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventCohort 2A (Non-randomized)Randomized Extension of Cohort 2A (3 Arms): C2A-IRandomized Extension of Cohort 2A (3 Arms): C2A-IIRandomized Extension of Cohort 2A (3 Arms): C2A-IIICohort 2B (Non-randomized)Cohort 3A (Non-randomized)Cohort 3B (Non-randomized)
SubileusGastrointestinal disorders0/260/131/20/40/70/130/5
GastroenteritisInfections and infestations0/260/130/20/40/70/131/5
Renal failureRenal and urinary disorders0/260/130/20/40/70/131/5
Cardiac failureCardiac disorders0/260/130/20/41/70/130/5
ConstipationGastrointestinal disorders0/260/130/20/40/71/130/5
Face oedemaGeneral disorders0/260/130/20/40/71/130/5
HyperthermiaGeneral disorders0/261/130/20/40/70/130/5
Mucosal inflammationGeneral disorders0/261/130/20/40/70/130/5
PyrexiaGeneral disorders2/260/130/20/40/70/130/5
HepatotoxicityHepatobiliary disorders0/261/130/20/40/70/130/5
Most frequent other events
Showing 10 of 239
Most frequent other events
EventCohort 2A (Non-randomized)Randomized Extension of Cohort 2A (3 Arms): C2A-IRandomized Extension of Cohort 2A (3 Arms): C2A-IIRandomized Extension of Cohort 2A (3 Arms): C2A-IIICohort 2B (Non-randomized)Cohort 3A (Non-randomized)Cohort 3B (Non-randomized)
Injection site reactionGeneral disorders9/266/132/20/43/76/132/5
AstheniaGeneral disorders4/269/130/21/42/72/132/5
DiarrhoeaGastrointestinal disorders9/264/130/20/43/72/133/5
Injection site painGeneral disorders5/262/130/20/40/74/133/5
Abdominal herniaGastrointestinal disorders0/260/131/20/40/70/130/5
Abdominal painGastrointestinal disorders5/263/131/21/40/71/131/5
Abdominal pain upperGastrointestinal disorders1/262/131/20/40/71/130/5
NauseaGastrointestinal disorders5/265/131/20/40/70/132/5
FatigueGeneral disorders6/261/131/21/43/73/130/5
Alanine aminotransferase increasedInvestigations4/263/131/21/42/71/130/5

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cohort 2A (Non-randomized)Randomized Extension of Cohort 2A (3 Arms): C2A-IRandomized Extension of Cohort 2A (3 Arms): C2A-IIRandomized Extension of Cohort 2A (3 Arms): C2A-IIICohort 2B (Non-randomized)Cohort 3A (Non-randomized)Cohort 3B (Non-randomized)Total
Median46 (31 to 61)54 (35 to 73)49.5 (38 to 61)52.5 (19 to 65)47 (43 to 72)55 (48 to 61)63 (36 to 64)51 (19 to 85)
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 2A (Non-randomized)Randomized Extension of Cohort 2A (3 Arms): C2A-IRandomized Extension of Cohort 2A (3 Arms): C2A-IIRandomized Extension of Cohort 2A (3 Arms): C2A-IIICohort 2B (Non-randomized)Cohort 3A (Non-randomized)Cohort 3B (Non-randomized)Total
Female18100374446
Male832109124
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 2A (Non-randomized)Randomized Extension of Cohort 2A (3 Arms): C2A-IRandomized Extension of Cohort 2A (3 Arms): C2A-IIRandomized Extension of Cohort 2A (3 Arms): C2A-IIICohort 2B (Non-randomized)Cohort 3A (Non-randomized)Cohort 3B (Non-randomized)Total
Hispanic or Latino00000011
Not Hispanic or Latino261324713469
Unknown or Not Reported00000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 2A (Non-randomized)Randomized Extension of Cohort 2A (3 Arms): C2A-IRandomized Extension of Cohort 2A (3 Arms): C2A-IIRandomized Extension of Cohort 2A (3 Arms): C2A-IIICohort 2B (Non-randomized)Cohort 3A (Non-randomized)Cohort 3B (Non-randomized)Total
American Indian or Alaska Native00000000
Asian00000000
Native Hawaiian or Other Pacific Islander00000000
Black or African American00000000
White261324713570
More than one race00000000
Unknown or Not Reported00000000
Region of Enrollment
Region of Enrollment(participants)Cohort 2A (Non-randomized)Randomized Extension of Cohort 2A (3 Arms): C2A-IRandomized Extension of Cohort 2A (3 Arms): C2A-IIRandomized Extension of Cohort 2A (3 Arms): C2A-IIICohort 2B (Non-randomized)Cohort 3A (Non-randomized)Cohort 3B (Non-randomized)Total
Sweden10000001
Netherlands521122013
United States00010113
Denmark00001001
Italy851125123
France760122321
Germany20000204
Spain30000104
08

Study locations

12 sites
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Rigshospitalet
    Copenhagen, 2100, Denmark
  • Chu Lille
    Lille, 59037, France
  • Centre Léon Bérard
    Lyon, 69008, France
  • Assistance Publique - Hôpitaux de Marseille - Hôpital Nord
    Marseille, 13915, France
  • Institut Gustave Roussy
    Villejuif, 94800, France
  • Lmu Klinikum
    München, Germany
  • Universitätsklinikum Würzburg
    Würzburg, 97080, Germany
  • Azienda Ospedaliera Spedali Civili
    Brescia, 25121, Italy
  • Amsterdam UMC, location VUmc
    Amsterdam, 1081, Netherlands
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Karolinska University Hospital
    Stockholm, 17176, Sweden
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Safety and efficacy data

Supporting information: Study protocol, Statistical analysis plan

Time frame: Oct 2025

Access criteria: Primary and key secondary outcomes

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2020 to primary completion in Oct 2024, 50 months.

Results were first posted in Jan 2026, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2019
First posted
Dec 5, 2019
StartActual
Jul 23, 2020
Primary completionActual
Oct 2, 2024
CompletionActual
Oct 2, 2024
Results first posted
Jan 30, 2026
Last update
Jan 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04187404
Lead sponsor
Enterome
Responsible party
Sponsor
First posted
Dec 5, 2019
Start date
Jul 23, 2020
Primary completion
Oct 2, 2024
Completion
Oct 2, 2024
Results posted
Jan 30, 2026
Last update
Jan 30, 2026

Study contacts

Jean-Michel Paillarse
study director · Enterome

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion